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To create an HIV-1 vaccine that generates sufﬁcient breadth of immune recognition to protect against
the genetically diverse forms of the circulating virus, we have been exploring vaccines based on
consensus and mosaic protein designs. Increasing the valency of a mosaic immunogen cocktail increases
epitope coverage but with diminishing returns, as increasingly rare epitopes are incorporated into the
mosaic proteins. In this study we compared the immunogenicity of 2-valent and 3-valent HIV-1
envelope mosaic immunogens in rhesus monkeys. Immunizations with the 3-valent mosaic immuno-
gens resulted in a modest increase in the breadth of vaccine-elicited T lymphocyte responses compared
to the 2-valent mosaic immunogens. However, the 3-valent mosaic immunogens elicited signiﬁcantly
higher neutralizing responses to Tier 1 viruses than the 2-valent mosaic immunogens. These ﬁndings
underscore the potential utility of polyvalent mosaic immunogens for eliciting both cellular and
humoral immune responses to HIV-1.
& 2012 Elsevier Inc. All rights reserved.Introduction
One of the major obstacles preventing the development of an
effective vaccine against HIV-1 is the extraordinary genetic diver-
sity of the virus. Immunogens derived from single HIV-1
sequences, when evaluated in nonhuman primate studies and in
human clinical trials, have elicited immune responses with limited
cross-reactivity (McElrath et al., 2008). In contrast, immunogens
created using group M consensus sequences have generated
cellular immune responses in nonhuman primates with improved
cross-clade breadth (Santra et al., 2008). Recent studies in mice
and nonhuman primates have shown that polyvalent mosaic
immunogens elicited cellular immune responses with even
greater breadth and depth than group M consensus immunogens
(Barouch et al., 2010; Kong et al., 2009; Santra et al., 2008).ll rights reserved.
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Letvin).Polyvalent mosaic immunogen sequences are derived from the
in silico recombination of sequences of natural strains of HIV-1.
This in silico recombination is done using a machine learning
algorithm that selects a set of protein sequences that resemble
natural proteins, but in combination optimize the coverage of the
diversity of epitope sequences that exist worldwide in HIV-1
strains (Barouch et al., 2010; Fischer et al., 2007; Thurmond et al.,
2008). The potential utility of these mosaic proteins for immuno-
gens in humans was recently demonstrated when Ndhlovu et al.
showed that processing of mosaic proteins generates epitope
peptides that are recognized by human CD8þ T cells (Ndhlovu
et al., 2011). Moreover, this strategy is also being explored for
immunization against other pathogens, including Chlamydia
(Nunes et al., 2010), Hepatitis C (Yusim et al., 2010), Ebola
(Grard et al., 2011), and type 2 porcine reproductive and respira-
tory syndrome viruses (Shi et al., 2010).
During the optimization process, if 2 mosaic immunogens are
generated, the mosaic design program assembles a pair of full-
length mosaic proteins that incorporate the 2 most common
forms of each potential epitope (where all 9-amino acid frag-
ments are considered potential epitopes). If 3 mosaic immuno-
gens are generated, a third variant of each potential epitope is
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cocktail increases the coverage of potential T cell epitopes. However,
this increased coverage comes with diminishing returns, as increas-
ingly rare epitopes are incorporated into the mosaic proteins as the
number of proteins in the vaccine cocktail is increased. In addition, as
more variants are added, each one becomes more dilute in the
vaccine cocktail. Thus the selection of the number of variant
sequences for inclusion in a mosaic vaccine cocktail must be
balanced by weighing increased coverage against the diminished
epitope peptide representation as well as the increased cost and
complexity associated with increasing the number of variant
sequences incorporated into a vaccine (Fischer et al., 2008, 2007;
Korber et al., 2009).
Here we experimentally evaluate the beneﬁt of increasing the
number of mosaic HIV Envelope (Env) proteins in a vaccine
cocktail from 2 to 3. We also compare the immunogenicity of
these vaccine constructs to a natural HIV immunogen and a M
group consensus immunogen, making use of data generated in
previous studies (Fischer et al., 2007, 2008; Korber et al., 2009). To
determine the relative beneﬁts of these types of immunogens, we
determine how many immune responses each construct elicits
that cross-react with representative circulating strains of HIV-1.
We assess this cross-reactivity by evaluating vaccine-elicited
cellular immune responses for both breadth, the number of
distinct targeted epitopes that are recognized, and depth, the number
of variants recognized per targeted epitope. We used Env vaccines in
this study so that we could study both T cell and B cell responses.Results
We monitored immune responses using peptide sets that fully
span diverse natural Env proteins, so we could directly determine
the number responses we generate to actual HIV-1 Env proteins
(Santra et al., 2008). In the past we have used 10 proteins for
these purposes that were selected to be representative of the
global diversity of HIV-1 (Santra et al., 2008). To determine if a
subset of 5 of these 10 proteins would be adequate for evaluating
immune breadth in this and future studies, we compared the
potential T cell epitope (PTE) or 9-mer coverage of a series of Env
immunogen sequences to different sets of envelopes. The series of
Env immunogen sequences in this comparison included the single
strains HXB2 and MN, the M group Consensus (CON-S) sequence,
and ﬁnally the 2-valent and 3-valent mosaic sequences (Fig. 1).Fig. 1. The coverage of potential T cell epitopes (PTEs) by different vaccine candidates. S
by the 5 Env proteins used to monitor this study (red), the 10 proteins used in a previo
sequences (blue). All proteins in each set were broken down into all possible PTEs (9 am
matches (dark shades), the fraction that differed by one amino acid (lighter shades) and
in the immunogen proteins were calculated. (For interpretation of the references to coFor each immunogen sequence, we calculated the coverage of all
9-mers in the collection of global envelope sequences in the
current Los Alamos database (Database), in a set of 10 divergent
natural envelope sequences used to estimate the breadth of vaccine
coverage in a previous nonhuman primate study (Santra et al., 2008),
and a subset of 5 of those 10 natural divergent envelope sequences.
The sets of 5 and 10 Env sequences were comparably representative
of 9-mer coverage based on the global HIV database, suggesting that
peptides derived from this set of 5 Env sequences would provide a
reasonable framework for estimating the breadth and depth of
vaccine coverage of circulating HIV-1 isolates worldwide (Fig. 1).
We therefore decided to use these 5 Env peptide series to monitor
T cell responses in the present study. These 5 diverse HIV Env protein
sequences included one each from clade A, B and G and two from
clade C (GenBank accession numbers: A1, AY371163; B1, AY561237;
G1, AY371121; C1, AY563169, and C3, AF457054, respectively
(see Santra 2008) for details).
Fig. 1 reveals important differences in the potential coverage
that might be induced by these various immunogens. Natural
proteins had very low levels of coverage of potential T cell
epitopes (PTEs), with MN matching only approximately 17% of
the PTE sequences found in the global database of circulating
strain M group strains (Fig. 1, blue bar). The CON-S immunogen
provided 26% coverage of PTEs, or a 1.6-fold increase relative to MN
(Fig. 1, blue bar). In contrast, a 3-valent mosaic Env immunogen
increased the coverage of PTE sequences to 44% (Fig. 1, blue bar).
A vaccination study in nonhuman primates was initiated to
evaluate the breadth and depth of cellular and humoral immune
responses elicited by 2-valent and 3-valent HIV-1 Env mosaic
immunogens. Thirty Mamu-An01-negative Indian-origin rhesus
monkeys were divided into three groups: two experimental
groups, each consisting of 12 monkeys, and a control group
consisting of 6 monkeys. One experimental group received
2-valent mosaic Env immunogens, the other experimental group
received 3-valent mosaic Env immunogens, and the control group
received empty vectors. Monkeys received priming immunizations
by the intramuscular route at weeks 0 and 4 with a total of 4 mg
plasmid DNA expressing 2-valent mosaic Env, 3-valent mosaic
Env, or a sham construct. The monkeys that received mosaic Env
plasmid DNA immunogens also received a single clade B Gag
plasmid DNA immunogen. At week 8, monkeys were boosted by
intramuscular immunizations with 1011 particles of recombinant
adenovirus serotype 5 (rAd5) expressing the same mosaic Env and
single clade B Gag genes. The vaccination strategy was adaptedhown is the coverage of PTEs by different vaccine candidates as would be detected
us study (green) (Santra et al., 2008) and the 2010 Los Alamos database of HIV-1
ino acid fragments) and each of these PTEs was considered. The fraction of perfect
the fraction that differed by two amino acids (light shades) from the 9-mers found
lor in this ﬁgure legend, the reader is referred to the web version of this article.)
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and an M group consensus Env immunogen (Santra et al., 2008);
we did this to facilitate a direct comparison of the data generated
in the two studies. These studies did, however, differ in that Gag
immunogens were included in the current study, but not in the
prior experiment comparing HXB2 and the M group consensus
Env immunization. Gag immunogens were added to the current
study because they would also be administered if mosaic immu-
nogens were to be evaluated in human populations. It should be
noted, however, that if strong T cell responses were made to Gag,
these responses might divert some of the T cell responses away
from Env (Ferre et al., 2010).
The breadth of the vaccine-elicited cellular immune responses
was evaluated by assessing peripheral blood T lymphocyte
recognition of the set of 5 different natural Env sequences
discussed above, using a peptide/IFN-g ELISpot assay and matrix
epitope mapping. Peripheral blood lymphocytes (PBL) from each
vaccinated monkey were evaluated for IFN-g ELISpot responses to
pools of 15-mers overlapping by 11 amino acids spanning each of
the 5 envelope sequences. Epitopes of each of the 5 indicator
envelope proteins recognized by PBL sampled from each of the
experimentally vaccinated monkeys were enumerated as previously
described (Santra et al., 2008). To determine if there were differ-
ences in the epitope recognition by PBL of monkeys vaccinated with
HXB2, the M group consensus, or the 2-valent and 3-valent mosaic
immunogens, we evaluated the number of epitope peptides recog-
nized per natural Env sequence for all immunized animals (Fig. 2A).
To compare the immunogenicity of each of the four vaccines, we
used a quasi-binomial regression model to study the number of
vaccine-elicited positive responses per animal per peptide series,
using a strategy similar to analyses described in previous studies
(Santra et al., 2008). No immunogen elicited a response that was
biased toward a particular clade or strain of virus. The HXB2 vaccine
elicited signiﬁcantly fewer epitope peptide responses per peptide
series than the other three immunogens. CON-S had an odds ratio
(OR) of 3.09, p¼8.3107 relative to HXB2; the 2-valent mosaic, an
OR of 3.95, p¼6.41010; and the 3-valent mosaic, an OR of 4.12,
p¼2.01010. The immunogens can be rank ordered on the basis
of odds ratio of the number of epitope responses they elicited
from lowest to highest: HXB25CON-So2-valent mosaico3-valent
mosaic, and this ordering is consistent with the median number of
epitope-speciﬁc responses per strain elicited by each vaccine; 1 for
HXB2, 2 for CON-S, 3 for 2-valent mosaic, and 4 for the 3-valent
mosaic (Fig. 2B). Further statistical comparisons were consistent
with our previous ﬁndings (Santra et al., 2010) that the CON-S
immunogens elicited fewer epitope peptide-speciﬁc responses than
the mosaic vaccines, but in this study the p-values showed only
a trend: 2-valent mosaic compared to CON-S had an OR 1.28
(p¼0.08), and 3-valent mosaic compared to CON-S had an OR of
1.33 (p¼0.04). Of note, in this analysis we are comparing results
from two different studies (the HXB2 and CON-S data was from
Santra et al., 2008, the 2 and 3 valent mosaics from the present
study). The numbers of epitope peptide-speciﬁc responses elicited
by the 2- and 3-valent mosaics were not statistically distinguishable.
We also evaluated the depth of T lymphocyte responses, the
diversity of sequences of a given epitope that might be recognized
by T lymphocytes of the vaccinated monkeys (Fig. 3). This was
estimated by counting the responses made to all variant peptides
from every epitopic region of the Env protein for each vaccinated
monkey. It was very common for the vaccine-elicited responses to
be strain speciﬁc, i.e., only 1 of 5 variant peptides was recognized
by the vaccine-elicited T cell population (Fig. 3). However, the
number of T cell responses that recognized an epitope in two or
more divergent strains was increased in the monkeys that
received polyvalent mosaic immunogens. We ﬁrst did a Fisher’s
exact test comparison of a 24 contingency table to compare thenumber of epitope-speciﬁc responses that recognized only 1 of the
5 variant strains to the number that recognized 2 or more strains;
the p-value was 0.0006, indicating there were vaccine-associated
differences in the depth of the elicited responses. As shown in
Fig. 3, more than 60% of the responses to the single valent CON-S
and HXB2 vaccines recognized only 1 of the 5 strains. In contrast,
the polyvalent mosaic vaccines elicited more cross-reactive
responses (Fisher’s exact p¼4105). At the other end of the
spectrum, there was a 4-fold greater representation of responses
that recognized epitopes derived from all 5 evaluated virus strains
in mosaic-vaccinated animals than in animals vaccinated with the
single antigens CON-S or MN. (12% compared to 3%). There was no
clear difference in the depth of T cell responses elicited by the 2-
and 3-valent mosaic immunogens.
Finally, we assessed the effect of increasing the valency of the
mosaic immunogens on humoral responses. Sera sampled from
immunized monkeys at week 13 were assessed for antibody
binding to puriﬁed BaL.01 and Du156.12 gp120 and 93TH057
gp120 core proteins by ELISA as previously described (Wu et al.,
2010) Both the 2- and 3-valent mosaic immunogens elicited
comparable titers of binding antibody responses to the Env
proteins used in the assays (Fig. 4A). We also assessed the
neutralizing antibody responses in the sera of immunized mon-
keys to a limited number of Tier 1 (viruses that are highly
sensitive to antibody-mediated neutralization) and Tier 2 (viruses
that are moderately sensitive to antibody-mediated neutraliza-
tion) viruses (Seaman et al., 2010). Interestingly, the 3-valent
mosaic immunogens elicited signiﬁcantly higher titer neutralizing
antibody responses to tier 1 viruses than the 2-valent mosaic
immunogens (Fig. 4B). However, the 2-valent and 3-valent mosaic
immunogens elicited comparable, very weak or undetectable
neutralizing antibody responses to tier 2 viruses (Fig. 4B). These
ﬁndings are comparable to the antibody responses elicited by
natural strain and consensus Env immunogens (data not shown).Discussion
An effective HIV-1 vaccine should elicit robust effector CD8þ T
cell responses that can contain virus replication and CD4þ T cell
responses that can potentiate both antibody and effector CD8þ T
cell responses. The ELISpot assay employed in the present study
does not differentiate between CD8þ and CD4þ T cell populations.
However, based on previous studies in mice, monkeys and humans
to evaluate plasmid DNA prime/recombinant adenovirus serotype
5 boost immunizations, it is likely that the vaccine-elicited cells in
the present study were predominantly CD8þ T cells (Santra et al.,
2005; Shiver et al., 2002; Sumida et al., 2004). It is encouraging that
the breadth and depth of the vaccine elicited cellular immune
responses induced in the present study by the 2- and 3-valent
mosaic immunogens were statistically comparable, since it would
be easier and less expensive to deploy a 2-valent immunogen. We
were limited, however, by practical constraints in the number of
animals that could be evaluated; thus the present study was
underpowered (data not shown) for demonstrating the small
increase in coverage that was predicted in increasing from 2-valent
to 3-valent Env mosaics immunogens (Fig. 1). Since the monkeys
that received the 3-valent mosaic immunogens developed T cell
responses with greater breadth and depth than monkeys that
received the 2-valent mosaic immunogens, it is possible that a
larger study may have shown a statistically signiﬁcant beneﬁt
associated with receiving the 3-valent mosaic vaccines.
The depth of the cellular immune responses elicited by the
polyvalent mosaic immunogens was greater than cellular
immune responses elicited by the natural and consensus immu-
nogens. Responses with greater depth may mediate greater
Fig. 2. Breadth of Env-speciﬁc T lymphocyte responses in the 12 individual monkeys from each experimental group, showing number of peptide epitopes recognized per
protein. (A) The breadth of the vaccine-elicited cellular immune responses was determined by assessing peripheral blood T lymphocyte recognition of 5 different envelope
sequences using a peptide/IFN-g ELISpot assay. PBL from each vaccinated monkey were evaluated for IFN-g ELISpot responses to pools of 15-mers overlapping by 11 amino
acids spanning each of the 5 selected envelope sequences. Epitopes of each of the 5 indicator envelope proteins recognized by PBL of each of the experimentally vaccinated
monkeys were enumerated by matrix mapping and conﬁrmation with individual peptides. If two overlapping peptides gave a positive response, it was counted as a single
response. The minimum numbers of possible T cell responses that can recognize each strain are shown. (B) A box plot showing the distribution of numbers of vaccine
responses per strain elicited by the different vaccines.
S. Santra et al. / Virology 428 (2012) 121–127124cross-recognition of diverse circulating forms of HIV-1 at the time
of initial exposure to the virus, and may be able to block common
mutational immune escape routes for the virus if a vaccine recipient
becomes infected. It is not clear if the mosaic immunogen-induced
increase in cross-reactivity is the result of selection of new T cell
clones that recognize the distinct epitope variants or selection of T
cell clones that have a greater cross-reactive potential. Mosaic
antigens are designed to include to the greatest extent possible
the most common variants of each potential T cell epitope, andthese common variants likely represent relatively the most ﬁt
immune escape variants.
There is an increasing appreciation for the importance of
vaccine-induced anti-Env antibody responses for preventing HIV-1
acquisition (Rerks-Ngarm et al., 2009). While mosaic immunogens
were designed to elicit cellular immune responses, it is interesting
that these vaccine constructs also elicited neutralizing antibodies.
This might have been due to improved cross-recognition of epitopes
in the Envs tested due to simultaneous presentation of epitope
Fig. 3. Depth of cross-reactive T cell responses elicited by various vaccines. The
peptides used for the ELISpot assays were designed to maintain their alignment, so
they could be directly compared between strains. For each animal, if a vaccine
response was found to a peptide, the cross-reactive potential of the response was
assessed by counting how many of the 5 test strains were targeted by the
response. For each vaccine, the PBL of a monkey that recognized only one strain
(blue) were tallied for all animals in the group. Similarly, PBL populations that
recognized 2 of the 5 strains (light blue), 3 of the 5 (purple), 4 of 5 (light green),
and all 5 strains (pink) are shown. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
S. Santra et al. / Virology 428 (2012) 121–127 125variants during antibody selection and afﬁnity maturation, or it
might have been due to the third mosaic adding additional epitopes
to the antibody response. However, these antibodies neutralized
only the easy-to-neutralize tier 1 viruses, but not more difﬁcult-to-
neutralize tier 2 viruses. Since tier 2 viruses are representative of the
transmitted viruses that are responsible for the world-wide AIDS
epidemic (Mascola et al., 2005), it is likely that complementing
immunogens will be needed to generate an effective anti-HIV-1 Env
antibody response. The profound impact of the increase from single
valent natural or consensus to 2 to 3 mosaic polyvalent vaccines on
the strength of the Tier 1 antibody response to diverse strains is,
however, intriguing. It is possible that exposure of antibodies to
epitope variants during their clonal evolution and afﬁnity matura-
tion may improve their breadth.Materials and methods
Experimental groups and immunization schedule
All animals were maintained in an Association for Assessment
and Accreditation of Laboratory Animal Care—accredited institution
and with the approval of the Animal Care and Use Committees ofthe National Institutes of Health and Harvard Medical School. Thirty
Mamu-A*01-negative Indian-origin rhesus monkeys were distribu-
ted into three groups—two experimental groups, each consisting of
12 monkeys, and a control group consisting of 6 monkeys. Immu-
nizations were done as described in the Results section.
Construction of the plasmid DNA vaccines
The 2-valent and 3-valent mosaic HIV Env proteins were
designed using the methods described by Fischer et al. (Fischer
et al., 2007). This strategy uses a genetic algorithm that maximizes
the coverage of potential epitopes for a given vaccine valency N
(where N is either 2 or 3 in this study) by selecting in silico
recombined sequences that in combination essentially contain the
N most common circulating epitope variants. The design of the
mosaic proteins is alignment-independent. Thus the highly variable
regions with many insertions and deletions, such as the V2 loop, are
spanned by identifying the most common potential variants in the
region in the same manner as the rest of the protein. Short stretches
of these regions can be so variable, however, that they are
essentially unique in every individual; in such cases the mosaic
will represent a variant that exists at least once in nature. Although
the proteins are artiﬁcial, they are intact HIV proteins; mosaic
antigens have been shown to process human T cell epitopes
naturally (Barouch et al., 2010). The clade B Gag plasmid DNA
was based on HXB2 strain as described before (Wu et al., 2005). All
the HIV immunogen genes were synthesized using human-pre-
ferred codons [GeneArt, Regensburg, Germany] (Huang et al., 2001).
The cDNAs were cloned into a plasmid expression vector, pCMV/R,
which mediates high-level expression and immunogenicity in vivo
(Barouch et al., 2005; Fischer et al., 2008; Yang et al., 2007).
Construction of the recombinant adenoviruses
The construction and propagation of the rAd5 vectors expres-
sing the same immunogens as in the plasmid DNA vaccines were
previously described (Einfeld et al., 2001). The total particle unit
{PU} titer was determined by absorbance (Mittereder et al., 1996).
HIV-1 Env peptide sets and design of peptide matrices
15-mer peptides overlapping by 11 amino acids, spanning the
entire HIV-1 Env were used. Five sets of HIV-1 Env peptides from
4 different clades were synthesized, 1 from clade A, 1 from clade
B, 2 from clade C and 1 from clade G.
Pooled peptide and peptide matrix IFN-g ELISpot assays
Multiscreen ninety-six well plates were coated overnight with
100 ml per well of 5 mg/ml anti-human interferon-g (IFN-g) (B27; BD
Pharmingen) in endotoxin-free Dulbecco’s-phosphate buffered saline
(D-PBS). The plates were then washed three times with D-PBS
containing 0.1% Tween-20 and blocked for 2 h with RPMI-1640
containing 10% FBS. Then peptide pools and 2105 PBMCs were
added to each well in 100 ml reaction volumes in triplicate for pooled
peptides assays and in duplicate for peptide matrix assays. Each
peptide in a pool was present at a 1 mg/ml concentration. Following
an 18 h incubation at 37 1C, the plates were washed nine times with
D-PBS/Tween-20 and once with distilled water. The plates were then
incubated with 2 mg/ml biotinylated rabbit anti-human IFN-g
(U-Cytech) for 2 h at room temperature, washed six times with
D-PBS containing 0.1% Tween-20, and incubated for 2.5 h with a
1:500 dilution of streptavidin-AP (Southern Biotechnology Associ-
ates). After ﬁve washes with D-PBS/Tween-20 and one with D-PBS,
the plates were developed with NBT/BCIP chromogen (Pierce),
stopped by washing with tap water, air dried, and read with an
Fig. 4. Vaccine-elicited binding antibody and neutralizing antibody responses. (A) Five weeks post-rAd5 boost serum samples were collected from monkeys vaccinated
with either 2-valent or 3-valent mosaic immunogens. Antibodies from these serum samples were assessed for binding to puriﬁed BaL.01 and Du156.12 gp120 and
93TH057 gp120 core envelope proteins by ELISA. (B) The sera were also assessed for the presence of neutralizing antibodies to a limited number of Tier 1 and Tier 2 viruses.
There was a signiﬁcant increase in the level of Tier 1 neutralization for each of the 3 strains tested in the 3-valent mosaic group (MN, p-value¼0.003, using a non-
parametric Wilcoxon rank sum test; MW965, p-value¼0.0007; and DJ263, p-value¼0.0004).
S. Santra et al. / Virology 428 (2012) 121–127126ELISpot reader (Cellular Technology Ltd.). The number of spot forming
cells per 106 PBMCs was calculated.
HIV-1 neutralization assays
Neutralization was measured using single-round-of-infection
HIV-1 Env-pseudoviruses and TZM-bl target cells, as described
previously (Li et al., 2005; Seaman et al., 2010; Wu et al., 2009).
Neutralization curves were ﬁt by nonlinear regression using a
5-parameter hill slope equation as previously described (Seaman
et al., 2010). The 50% and 80% inhibitory concentrations (IC50 and
IC80) were reported as the antibody concentrations required to
inhibit infection by 50% and 80% respectively.
gp120 ELISAs
Binding of antibodies to puriﬁed gp120s was assessed by ELISA
as previously described (Wu et al., 2010). Brieﬂy, 200 ng ofpuriﬁed recombinant gp120 was adsorbed onto Reacti-Bind
96-well plates (Pierce), followed by blocking and incubation of
serially diluted antibodies. Bound antibody was detected using a
horseradish peroxidaseconjugated goat anti-human IgG Fc anti-
body (Jackson ImmunoResearch Laboratories). Plates were devel-
oped using SureBlue 3,30,5,50-tetramethylbenzidine (Kirkegaard
& Perry Laboratories). Puriﬁed gp120 proteins were full-length
gp120 BaL (Clade B), full-length gp120 DU156 (Clade C), or gp120
core 93TH057 (Clade E).
Statistics
All statistical analyses in this study were performed in R (www.
r-project.org/). To predict the probability of a positive response as
a function of vaccine group and strain, we ﬁt the number of
reactive peptides per strain as binomial counts in a generalized
linear model. We used a quasi-binomial model to appropriately
adjust the standard errors and p-values given evidence of slightly
S. Santra et al. / Virology 428 (2012) 121–127 127overdispersed data (dispersion parameter¼1.88). Vaccine effect
did not signiﬁcantly vary according to strain, nor did strain
signiﬁcantly impact the probability of eliciting a positive response.
Thus, we did not ﬁnd it necessary to adjust for these variables in
the ﬁnal model. All pairwise comparisons of the vaccine groups
were considered, and the signiﬁcance level (a¼0.05) was adjusted
accordingly. We also assessed the relationship between depth of
response and vaccine group via Fisher’s exact test, and compared
the magnitude of the Tier 1 antibody responses using a Wilcoxon
rank statistic.Acknowledgment
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